Search

Women make up 58% of all R&D staff, but hold only 24.4% of executive positions in the biotech sector

Navarra advances in the Comprehensive Strategy for Personalized Medicine with the constitution of the body that will coordinate its execution

This key addition will strengthen the Ysios Capital team, which is currently investing its fund Ysios BioFund III.

For International Rare Disease Day, we wanted to look more closely at the work our members are doing to find solutions to these very special conditions. We spoke with two of them about achievements

Over 80% of Spanish scientists abroad surveyed would like to return to Spain, but only 24% really know about the opportunities available. Offering attractive career prospects and competitive financial

The company conducted a retrospective study based on the records of patients hospitalized due to endometriosis and treated in Spanish public and private hospitals between January of 2009 and December

El Foro Premios Afectivo-Efectivo reconoce cada año las buenas prácticas de proyectos de salud realizados en España

The Stanford University ranking lists the 2% of the world's most cited researchers according to their scientific trajectory. The new edition also lists Anitua as the most relevant Spanish researcher

It is private funding that allows progress to be made in highly costly stages such as clinical validation

Key to advancing development of the FiCAT gene writing platform, which aims to resolve the main limitations of gene therapy

Natac has officially announced that the Hervás manufacturing facility received its organic certification. The certification is intended to meet the needs of partners and industry professionals, as

Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund and Asabys Partners Unique Protein Splicing platform enables

This study, carried out in collaboration with Solutia, compiles the salary trends transforming the dynamics of the national labour market

Oryzon Genomics, S.A., a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management